BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...
BioCentury | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

...least two companies have GM1 gangliosidosis gene therapies in preclinical development: Axovant Sciences Ltd. has AXO-AAV-GM1...
BioCentury | Mar 11, 2019
Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
BioCentury | Dec 21, 2018
Company News

Axovant gets rights to gene therapies from UMass medical school

...well as $39.8 million in commercial milestones, plus tiered mid-single-digit royalties. The first program, dubbed AXO-AAV-GM1...
Items per page:
1 - 4 of 4